Qantas shares slide to 6-mth low as airline trims revenue outlook
Arcellx, Inc. (NASDAQ:ACLX) Chief Financial Officer Michelle Gilson sold 5,364 shares of the company’s common stock on October 15, 2025, for approximately $488,315. The shares were sold at a weighted average price of $91.0357, in a price range of $90.99 to $91.19. The transaction comes as InvestingPro data shows ACLX has delivered an impressive 50% return over the past six months, with the stock currently trading near its 52-week high of $107.37.
Following the transaction, Gilson directly owns 8,466 shares of Arcellx , Inc.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan established on March 21, 2025.
In other recent news, Scotiabank raised its price target for Arcellx Inc. to $133 from $93. This adjustment comes while maintaining a Sector Outperform rating on the stock. The increase in the price target follows the departure of Vinay Prasad, the recently installed head of the FDA’s Center for Biologics Evaluation and Research. Scotiabank views this departure as removing a regulatory overhang for the company. These developments are part of the latest updates surrounding Arcellx, which could influence investor perspectives. The adjustments by Scotiabank reflect their analysis of the current regulatory environment impacting Arcellx. Investors might find these insights useful for understanding the company’s recent trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.